ncRNA basic information ncRNA ID: MIMAT0000617 ncRNA Database: miRBase ncRNA Name: miR-200c-3p ncRNA Type: miRNA ncRNA Expression: down-regulated ncRNA Method: RT-qPCR ncRNA Target Gene: SOX2 ncRNA Pathway: NA Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Drug Name: Paclitaxel Drug Method: The aim of the present study was to investigate the role and mechanism of action of miR-200c-3p in the resistance of breast cancer to paclitaxel. It was observed that miR-200c-3p expression, as determined by reverse transcription-quantitative polymerase chain reaction analysis, was significantly downregulated in paclitaxel-resistant MCF-7/Tax cells compared with parental MCF-7 cells. Overexpression of miR-200c-3p increased the chemosensitivity to paclitaxel and enhanced apoptosis in MCF-7/Tax cells, whereas the downregulation of miR-200c-3p exerted the opposite effect. In addition, upregulation of miR-200c-3p in MCF-7/Tax cells suppressed the expression of sex-determining region Y-box 2 (SOX2) at the mRNA and protein levels. Dual-luciferase reporter assay demonstrated that SOX2 is a target of miR-200c-3p in MCF-7/Tax cells. Moreover, knockdown of SOX2 expression increased chemosensitivity to paclitaxel and upregulated miR-200c-3p expression in MCF-7/Tax cells. Drug Response: resistant

Cancer basic information Cancer: breast cancer Tissue/Cell: cell line (MCF-7,MCF-7/Tax)

Other information Title: Downregulation of miR-200c-3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2. Journal: Oncol Rep Published: 2018 PubMed ID: 30272330